TrialNature communications2026

L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial.

Frank A Giordano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.